 Pioglitazone protects PCOS patients
Pioglitazone protects PCOS patients
Source: Fertility and Sterility 2006; 86: 385-97
Examining the mechanisms of insulin resistance and the effects of pioglitazone treatment on insulin resistance in women with polycystic ovary syndrome.
The thiazolidinedione pioglitazone has shown potential to prevent progression to type 2 diabetes in women with polycystic ovary syndrome (PCOS) in a small, randomized, placebo-controlled trial.
Thirty obese women with PCOS and 14 healthy women, matched for weight, were enrolled to examine the basis of insulin resistance in PCOS and the effects of pioglitazone. The women were treated with pioglitazone or placebo for 16 weeks. At the beginning and end of this intervention period, fasting blood samples were taken and euglycemic clamps were performed.
Dorte Glintborg (Odense University Hospital, Denmark) and colleagues report that the PCOS patients had significantly lower insulin sensitivity than controls, including decreased insulin-stimulated oxidative and nonoxidative glucose metabolism.
However, treatment with pioglitazone significantly reduced fasting insulin levels and significantly increased insulin sensitivity. It also increased oxidative and nonoxidative glucose metabolism, while reducing lipid metabolism and levels of free fatty acids.
The researchers say these results make pioglitazone "a potential treatment for protecting patients with PCOS from developing type 2 diabetes."
Posted: 3 August 2006
__________________
To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts.
To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts. To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts. | 
